行情

BHVN

BHVN

Biohaven Pharma
NYSE

实时行情|Nasdaq Last Sale

51.56
-0.03
-0.06%
盘后: 51.56 0 0.00% 16:31 11/19 EST
开盘
52.00
昨收
51.59
最高
52.84
最低
51.09
成交量
60.19万
成交额
--
52周最高
67.86
52周最低
29.17
市值
26.93亿
市盈率(TTM)
-5.7635
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BHVN 新闻

  • Biohaven Readies for ‘David Versus Goliath’ Battle with Allergan
  • Bloomberg.6天前
  • Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
  • PR Newswire.11/06 14:02
  • Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
  • PR Newswire.11/05 12:30
  • Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
  • PR Newswire.11/04 23:43

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

BHVN 简况

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
展开

Webull提供Biohaven Pharmaceutical Holding Co Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。